BioSpace News Archive

Seven Presentations Will Include Unique Research on the New Biotrue ® Hydration Plus Multi-Purpose Solution and Biotrue ® Hydration Boost Lubricant Eye Drops.

Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Interim Analysis Findings Support Continued Evaluation of Both Monotherapy and Combination Therapy.

Bruker Launches timsTOF HT with Greater Dynamic Range for Further Enhancing Unbiased, High-Confidence 4D Proteomics ™.

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that it will host a virtual Research and Development Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET.

Biogen Inc. (Nasdaq: BIIB) – Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease (PD).

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of the management team will participate in the following upcoming investor conferences.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the first patient dosed in a Phase 2a clinical trial.

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P<0.0001).

Over 5,000 individuals with clinical levels of depression and comorbid anxiety who completed CloudMD’s Therapist Assisted iCBT program experienced reliable symptom improvement.